Tredegar Corporation (TG): Price and Financial Metrics


Tredegar Corporation (TG): $14.98

-0.12 (-0.79%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

TG Stock Summary

  • Tredegar Corp's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 94.47% of US listed stocks.
  • With a year-over-year growth in debt of 140.91%, Tredegar Corp's debt growth rate surpasses 91.83% of about US stocks.
  • Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for TG comes in at 24.66% -- higher than that of 92.31% of stocks in our set.
  • If you're looking for stocks that are quantitatively similar to Tredegar Corp, a group of peers worth examining would be YPF, SWBI, GVP, NVT, and WEI.
  • Visit TG's SEC page to see the company's official filings. To visit the company's web site, go to www.tredegar.com.

TG Stock Price Chart Interactive Chart >

Price chart for TG

TG Price/Volume Stats

Current price $14.98 52-week high $23.71
Prev. close $15.10 52-week low $12.80
Day low $14.75 Volume 68,952
Day high $15.16 Avg. volume 169,146
50-day MA $15.82 Dividend yield 3.18%
200-day MA $16.35 Market Cap 502.40M

Tredegar Corporation (TG) Company Bio


Tredegar Corporation manufactures and sells plastic films and aluminum extrusions worldwide. It operates through two segments, Film Products and Aluminum Extrusions. The company was founded in 1988 and is based in Richmond, Virginia.

TG Price Forecast Based on DCF Valuation

Current PriceDCF Fair Value Target: Forecasted Gain:
$14.98$18.16 20%

We started the process of determining a valid price forecast for Tredegar Corp with a discounted cash flow analysis -- the results of which can be found in the table below. To summarize, we found that Tredegar Corp ranked in the 59th percentile in terms of potential gain offered. Moreover, under all the scenarios we modelled, the output consistently forecasted positive returns. As for the metrics that stood out in our discounted cash flow analysis of Tredegar Corp, consider:

  • Tredegar Corp's weighted average cost of capital (WACC) is 12%; for context, that number is higher than 79.44% of tickers in our DCF set.
  • Tredegar Corp's interest coverage rate -- a measure of gross earnings relative to interest payments -- comes in at -31.34. This coverage rate is greater than that of only 3.82% of stocks we're observing for the purpose of forecasting via discounted cash flows.
  • The company's cost of debt, derived from its interest coverage, tax rate, and market capitalization, is greater than 78.99% of stocks in its sector (Basic Materials).


Terminal Growth Rate in Free Cash FlowReturn Relative to Current Share Price
0%18%
1%19%
2%20%
3%21%
4%23%
5%24%

FUL, FF, USAP, CSTE, and AUY can be thought of as valuation peers to TG, in the sense that they are in the Basic Materials sector and have a similar price forecast based on DCF valuation.


TG Latest News Stream


Event/Time News Detail
Loading, please wait...

TG Latest Social Stream


Loading social stream, please wait...

View Full TG Social Stream

Latest TG News From Around the Web

Below are the latest news stories about Tredegar Corp that investors may wish to consider to help them evaluate TG as an investment opportunity.

Tredegar Reports Fourth Quarter and Full Year 2020 Results

Tredegar Corporation (NYSE:TG, also the "Company" or "Tredegar") today reported fourth quarter and full year financial results for the period ended December 31, 2020.

Yahoo | March 16, 2021

TSLOTS Aluminum Framing System is Expanding Operations

TSLOTS Framing System is Expanding Operations

Yahoo | March 4, 2021

New 200-place Welsh school planned for Tredegar enters phase two

Extra school places could be created as part of the primary in Blaenau Gwent

Wales Online | February 24, 2021

TG’s Ukoniq Gets FDA Nod For Lymphoma Therapies; Shares Pop 12%

Shares of TG Therapeutics spiked 12% on Feb. 5 after the US Food and Drug Administration (FDA) approved Ukoniq (umbralisib), its investigational compound, for the treatment of adult patients with relapsed or refractory marginal zone lymphoma (MZL). The stock gained another 4% in Friday's after-hours trading. Specifically, the FDA granted approval for the treatment of Ukoniq in MZL patients who have received at least one prior anti-CD20 based regimen and adult patients with relapsed or refractory follicular lymphoma (FL) who have received at least three prior lines of systemic therapy. TG Therapeutics (TGTX) is a biopharma company focused on the development of novel treatments for B-cell malignancies and autoimmune diseases.

Sharon Wrobel on TipRanks | February 7, 2021

Herefordshire sawmill fined after Tredegar worker crushed and killed by machine

A SAWMILL in Herefordshire has been fined £200,000 after a man was crushed and killed while at work there three years ago.

South Wales Argus | February 2, 2021

Read More 'TG' Stories Here

TG Price Returns

1-mo -8.49%
3-mo -6.86%
6-mo 86.39%
1-year 91.94%
3-year 70.12%
5-year 98.84%
YTD -9.71%
2020 48.04%
2019 44.44%
2018 -15.51%
2017 -17.97%
2016 80.67%

TG Dividends

Ex-Dividend Date Type Payout Amount Change
Loading, please wait...
View Full TG Dividend History

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!

Page generated in 1.0937 seconds.